prikaz prve stranice dokumenta Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)
  Preuzmi
PDF 391.14 KB
Znanstveni rad - Pregledni rad
Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)
Molecular Medicine Reports, 24 (2021), 2; 611. https://doi.org/10.3892/mmr.2021.12250
Nadalin, Sergej; Jakovac, Hrvoje; Peitl, Vjekoslav; Karlović, Dalibor; Buretić-Tomljanović, Alena

Povezani objekti
COVID-19 | Virtualna zbirka
Citirajte ovaj rad

Nadalin, S., Jakovac, H., Peitl, V., Karlović, D. i Buretić Tomljanović, A. (2021). Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review). Molecular Medicine Reports, 24. (2). doi: 10.3892/mmr.2021.12250

Nadalin, Sergej, et al. "Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)." Molecular Medicine Reports, vol. 24, br. 2, 2021. https://doi.org/10.3892/mmr.2021.12250

Nadalin, Sergej, Hrvoje Jakovac, Vjekoslav Peitl, Dalibor Karlović i Alena Buretić Tomljanović. "Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)." Molecular Medicine Reports 24, br. 2 (2021). https://doi.org/10.3892/mmr.2021.12250

Nadalin, S., et al. (2021) 'Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)', Molecular Medicine Reports, 24(2). doi: 10.3892/mmr.2021.12250

Nadalin S, Jakovac H, Peitl V, Karlović D, Buretić Tomljanović A. Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review). Molecular Medicine Reports [Internet]. 28.06.2021. [pristupljeno 25.12.2024.];24(2). doi: 10.3892/mmr.2021.12250

S. Nadalin, H. Jakovac, V. Peitl, D. Karlović i A. Buretić Tomljanović, "Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)", Molecular Medicine Reports, vol. 24, br. 2, Lipanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:410278. [Citirano: 25.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:410278
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)
AutorSergej Nadalin
AutorHrvoje Jakovac
AutorVjekoslav Peitl
AutorDalibor Karlović
AutorAlena Buretić-Tomljanović
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za fiziologiju, imunologiju i patofiziologiju)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku biologiju i genetiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Genetika, genomika i proteomika čovjeka
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Imunologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Psihijatrija
Sažetak (engleski)
Genetic and nongenetic factors associated with an increased inflammatory response may mediate a link between severe coronavirus disease 2019 (COVID‑19) and serious mental illness (SMI). However, systematic assessment of inflammatory response‑related factors associated with SMI that could influence COVID‑19 outcomes is lacking. In the present review, dietary patterns, smoking and the use of psychotropic medications are discussed as potential extrinsic risk factors and angiotensin‑converting enzyme (ACE) insertion/deletion (I/D) gene polymorphisms are considered as potential intrinsic risk factors. A genetics‑based prediction model for SMI using ACE‑I/D genotyping is also proposed for use in patients experiencing severe COVID‑19. Furthermore, the literature suggests that ACE inhibitors may have protective effects against SMI or severe COVID‑19, which is often linked to hypertension and other cardiovascular comorbidities. For this reason, we hypothesize that using these medications to treat patients with severe COVID‑19 might yield improved outcomes, including in the context of SMI associated with COVID‑19.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMolecular Medicine Reports
Brojčani podacivol. 24, br. 2, 611
p-ISSN1791-2997
e-ISSN1791-3004
DOIhttps://doi.org/10.3892/mmr.2021.12250
URN:NBNurn:nbn:hr:184:410278
Datum objave elektroničkog izdanja2021-06-28
URL dokumentahttp://www.spandidos-publications.com/10.3892/mmr.2021.12250
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2021-09-07 09:23:33